What Happened?

Shares of biotech company 10x Genomics (NASDAQ: TXG) jumped 2.5% in the afternoon session after several analysts raised their price targets on the stock, pointing to a more optimistic outlook for the life sciences sector. 

Barclays increased its price target on 10x Genomics to $22 from $17. The firm noted that recovering end markets and the tools space being under-owned created a good setup for outperformance. In a similar move, BofA raised its price target to $18 from $15, stating that headwinds were expected to fade and markets were set to normalize. Canaccord also lifted its price target to $20. This analyst activity reflected a broader renewed, though cautious, optimism across the biopharmaceutical industry heading into the year, with investment sentiment strengthening.

After the initial pop the shares cooled down to $16.42, up 0.7% from previous close.

Is now the time to buy 10x Genomics? Access our full analysis report here.

What Is The Market Telling Us

10x Genomics’s shares are extremely volatile and have had 50 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 11 days ago when the stock gained 4.8% on the news that Canaccord Genuity maintained its 'Buy' rating and raised its price target on the company's shares. 

The firm increased its price target from $19.00 to $20.00, signaling continued confidence in the company's performance. This move followed other recent positive analyst sentiment. Just a week earlier, Barclays also increased its price target on the stock to $22 from $17, maintaining an 'Overweight' rating. The Barclays analyst cited expectations of stabilizing end-market demand and improving conditions for research funding as reasons for the positive outlook on the life sciences tools sector.

Investors who bought $1,000 worth of 10x Genomics’s shares 5 years ago would now be looking at an investment worth $116.85.

The 1999 book Gorilla Game predicted Microsoft and Apple would dominate tech before it happened. Its thesis? Identify the platform winners early. Today, enterprise software companies embedding generative AI are becoming the new gorillas. Click here for access to our special report that reveals one profitable leader already riding this wave.